NSG BioLabs, Singapore's largest provider of biotech co-working laboratory and office space, and the Life Science business of Merck Singapore, have announced partnership giving biotech startups access to resources and expertise to bolster the research and development capabilities of NSG Biolabs' tenants, thereby facilitating opportunities for funding, partnerships, production, and commercialisation.

Speaking on the collaboration, Chua Keng Hock, Managing Director of Merck Singapore, and Senior Vice President of Process Solutions for APAC said, "Merck Singapore's partnership with NSG Biolabs underscores our commitment to supporting the growth and development of the biotech community in Singapore and across Asia Pacific. Merck offers one of the broadest portfolios in the industry for research discovery to pharmaceutical development and testing, and manufacturing of traditional and novel modalities, and access to the M Lab Collaboration Center in Singapore for off-site trial support and training on large equipment in a GMP-like environment."

Since 2019, NSG BioLabs has been assisting innovators in creating impactful solutions in the health, biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, synthetic biology, and other areas. With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with local and international partners, suppliers, and industry experts, NSG BioLabs has helped over 40 companies as residents. The company's residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones. The startup residents alone have successfully raised nearly $400 million in funding and supported hundreds of jobs.